Cancer Drugs News
Most Popular Cancer Drugs Story
Revlimid price likely to attract price scrutiny
Celgene says it will sell the newly-approved Revlimid for $6,195 a month to patients with multiple myeloma. Analysts note that each new cancer drug that is approved is coming out with a price higher than competing drugs currently on the market. That's a trend that can be sustained for now, analysts note, but won't be sustainable indefinitely. Morgan Stanley concludes that the drug will garner a 97 percent gross profit, which doesn't include the cost of marketing or administrative …
... Read more...Latest Headlines
- February 2, 2010
- December 11, 2009
- September 10, 2009
- September 2, 2009
- July 23, 2009
- April 21, 2009
- November 20, 2008
- November 18, 2008
- October 21, 2008
- August 8, 2008
- June 3, 2008
- May 15, 2008
- May 14, 2008
- April 28, 2008
- April 22, 2008
- April 16, 2008
- April 15, 2008
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
